Loading company…
Prosit Sole develops protein therapeutics, including drug candidates for rare diseases.
Established in 2013 and based in Beijing, China, Prosit Sole develops protein therapeutics. It operates an R&D center and manufacturing facility in Hebei and a clinical research center in Seattle. Its Prositsole Protein Optimize Platform supports drug screening, cell banking and animal disease models. The company has six innovative drug candidates in its pipeline and raised Series B funding led by Longmen Capital in February 2021.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in